Latest Metastat Inc (MTST) Headlines
MetaStat, Inc. Announces Issuance of New U.S. Patent for its MetaSite Breast(tm) Test
ACCESSWIRE - Thu Mar 06, 7:41AM CST
MONTCLAIR, N.J. / ACCESSWIRE / March 6, 2014 / MetaStat, Inc. (OTCQB : MTST), a life science company focused on understanding and treating systemic metastasis, announced today that the United States Patent and Trademark Office (USPTO) issued on February 4, 2014, U.S. Patent No. 8,642,277 entitled: "TUMOR MICROENVIRONMENT OF METASTASIS (TMEM) AND USES THEREOF IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF TUMORS." The named inventors of this new patent are John Condeelis, Thomas E. Rohan, Frank B. Gertler, and Joan G Jones.
MetaStat, Inc. to Present at the 26th Annual ROTH Conference
Marketwire - Wed Feb 26, 6:15AM CST
MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today that it has been invited to present at the upcoming 26th Annual ROTH Conference. The conference will be held on March 9-12, 2014 at The Ritz-Carlton Laguna Niguel in Dana Point, California. MetaStat will be presenting on Wednesday, March 12, 2014 at 12:30 pm (PT).
Rightscorp Innovative Business Model Persuades File Sharing Users to Pay Intellectual Property Holders: Updates on Recent Coverage
PR Newswire - Tue Feb 25, 6:00AM CST
A California company, Rightscorp, Inc. (OTCQB: RIHT) is receiving the blessing of major music and movie studios by going after illegal distributors on file-sharing sites in a different way than previous enforcement methods. Shareholders seem encouraged as well, especially since this type of low-level piracy is likely to continue.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Metastat Analyst Report Provides Investor Opportunity
PR Newswire - Mon Feb 17, 6:00AM CST
With the tremendous run in the biotech sector over the last 12 months many have overlooked this micro-cap gem that has terrific upside potential. Metastat, Inc. (OTCQB: MTST) is a life sciences company that provides proprietary platform technologies for the treatment of systemic metastasis. This micro-cap stock is topping the list for many analyst in the coming year.
MetaStat, Inc. Launches Scientific Advisory Board for Therapeutics
ACCESSWIRE - Mon Feb 10, 7:00AM CST
MONTCLAIR, NJ / ACCESSWIRE / February 10, 2014 / MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced the appointments of scientific and clinical leaders from the fields of RNA biology, alternative splicing, and therapeutic resistance in cancer to its newly formed scientific advisory board for therapeutics. The members include David M. Epstein, Ph.D, Eric Winer, M.D., Adrian Krainer, Ph.D., Mariano-Garcia Blanco, M.D., Ph.D., Michael Hemann, M.D., Ph.D. and Frank Gertler, Ph.D.
MetaStat, Inc. to Present at the 2014 BIO CEO & Investor Conference in New York City on February 11, 2014
ACCESSWIRE - Wed Feb 05, 8:03AM CST
MONTCLAIR, NJ / February 5, 2014 / ACCESSWIRE / MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced that the company's Chief Executive Officer, Oscar Bronsther, M.D., will present at the BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 1:30 p.m. EST. The conference will be held at the Waldorf Astoria in New York. Dr. Bronsther will discuss MetaStat's novel diagnostic and therapeutic approaches to systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body.
Fundamentals of Endotoxin Testing for Medical Device Manufacturers are Detailed in New Technical Brief
Business Wire - Tue Jan 14, 9:12AM CST
The fundamentals of endotoxin testing for medical device manufacturers -- from definition to assay acceptance criteria --are detailed in new technical brief available from Microtest Laboratories.
MetaStat, Inc. to Present at Biotech Showcase(TM) 2014 in San Francisco
Marketwire - Wed Jan 08, 11:12AM CST
MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced that the company's Chief Executive Officer, Oscar Bronsther, M.D., will present at the Biotech Showcase(TM) 2014 on Wednesday, January 15th at 9:30am PST. Dr. Bronsther will discuss MetaStat's novel diagnostic and therapeutic approaches to systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. To arrange a one-on-one meeting with management, please contact Andrew Haag at mtst@irthcommunications.com or 1-866-976-IRTH.
Fidelity & Guaranty Life Holdings, Inc. Announces Year End 2013 Conference Call for Bondholders
PR Newswire - Tue Jan 07, 8:52AM CST
Fidelity & Guaranty Life Holdings, Inc. ("FGLH") today announced the date and time of its quarterly bondholder conference call for the Fiscal year ended September 30, 2013. The call is open to all holders of Fidelity & Guaranty Life Holdings, Inc. 6.375% senior unsecured notes due 2021.
MetaStat, Inc. Announces Issuance of U.S. Patent for Its MenaCalc(TM) Platform
Marketwire - Mon Dec 23, 7:30AM CST
MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent Number US 8,603,738 entitled: "METASTASIS SPECIFIC SPLICE VARIANTS OF MENA AND USES THEROF IN DIAGNOSIS, PROGNOSIS, AND TREATMENT OF TUMORS", Inventors: John Condeelis, Sumanta Goswami, Frank Gertler, and Paola Nistico.
MetaStat Announces Poster Presentation at the 2013 San Antonio Breast Cancer Symposium
Marketwire - Tue Dec 17, 9:13AM CST
MetaStat, Inc. (OTCBB: MTST), a life sciences company focused on understanding and treating systemic metastasis, today announced data on the company's licensed metastatic breast cancer diagnostic has been presented in Poster Session P2-11-03 entitled "A tumor microenvironment of metastasis (TMEM) biomarker in early breast cancer provides prognostic information that is complementary to IHC4: A prospective validation study" at the CTRC-AACR 2013 San Antonio Breast Cancer Symposium on December 10-14, 2013, in San Antonio, Texas.
MetaStat Announces Exclusive Worldwide License Agreements for the Alternative Splicing Program in the Epithelial to Mesenchymal Transition (EMT) in Epithelial Cancers
Marketwire - Thu Dec 12, 8:30AM CST
MetaStat, Inc. (OTCQB: MTST), a life sciences company focused on understanding and treating systemic metastasis, today announced that the company has entered into two separate exclusive worldwide patent and technology license agreements (the "Agreements") with The Massachusetts Institute of Technology ("MIT") and its David H. Koch Institute for Integrative Cancer Research at MIT and its Department of Biology, Albert Einstein College of Medicine of Yeshiva University, and Montefiore Medical Center. The Agreements cover the use of alternatively spliced mRNA and protein isoform markers for the diagnosis, prognosis and treatment of metastasis in epithelial solid tumor cancers. The company believes this technology bolsters its intellectual property position surrounding the use of the Mena protein isoforms in the diagnosis, prognosis and treatment of metastasis in epithelial cancers. Further, this technology provides MetaStat with a number of additional targets for its companion diagnostic and therapeutic programs.
Microtest Laboratories Offers OECD Fish Embryo Toxicity Testing
PR Newswire - Tue Dec 03, 11:17AM CST
Microtest Laboratories, a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries, is adding OECD Fish Embryo Toxicity Testing to its portfolio of services.
MetaStat, Inc. Announces Notice of Allowance for a U.S. Patent Supporting Its MenaCalc(TM) Platform
Marketwire - Mon Nov 11, 7:41AM CST
MetaStat, Inc. (OTCBB: MTST), a life sciences company focused on understanding and treating systemic metastasis, today announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent entitled: "METASTASIS SPECIFIC SPLICE VARIANTS OF MENA AND USES THEROF IN DIAGNOSIS, PROGNOSIS, AND TREATMENT OF TUMORS." MetaStat holds a license to this patent (US Patent Application. No. 12/462,324), which claims center on the Company's MenaCalc(TM) diagnostic platform. The Notice of Allowance is the USPTO's official communication that the patent application has successfully completed examination and that a patent will be issued. When issued, the patent will have a term that expires no earlier than in 2028.
MetaStat, Inc. Announces Notice of Allowance for a U.S. Patent Supporting Its MetaSite Breast(TM) Test
Marketwire - Wed Nov 06, 7:00AM CST
MetaStat, Inc. (OTCBB: MTST), a life sciences company focused on understanding and treating systemic metastasis, today announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent entitled: "TUMOR MICROENVIRONMENT OF METASTASIS (TMEM) AND USES THEREOF IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF TUMORS." MetaStat holds a license to this patent (US Patent Application. No. 12/804,779), which claims center on the Company's MetaSite Breast(TM) diagnostic assay. The Notice of Allowance is the USPTO's official communication that the patent application has successfully completed examination and that a patent will be issued. When issued, the patent will have a term that expires no earlier than in 2030.
Use of Stability Studies in Drug, Combination Products & Medical Device Development are Reviewed in New Whitepaper
Business Wire - Tue Oct 22, 8:13AM CDT
The use of stability testing in new product development -- of drug substances, drug products, combination products and some medical devices -- is reviewed in a new whitepaper from Microtest Laboratories, a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries.
MetaStat Announces Commencement of Its Comprehensive Drug Development Program with Significant New Hires and Research Facility Opening
ACCESSWIRE - Tue Sep 10, 6:05AM CDT
Montclair, NJ, (Accesswire - September 10, 2013) - MetaStat Inc. (OTCBB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced that it has commenced its comprehensive drug development program with the hiring of Elizabeth Buck, Ph.D. and Matthew O'Connor, both formerly of OSI Pharmaceuticals, Inc. (acquired by Astellas Pharma, Inc.), along with the opening of its new drug discovery research facility located in Stony Brook, NY. Both Dr. Buck and Mr. O'Connor will work closely and in collaboration with Dr. David Epstein, MetaStat's Head of Drug Development and former Chief Scientific Officer of OSI Pharmaceuticals.
MetaStat, Inc. Announces Issuance of New U.S. Patent for its MetaSite Breast(tm) Test
ACCESSWIRE - Thu Mar 06, 7:41AM CST
MONTCLAIR, N.J. / ACCESSWIRE / March 6, 2014 / MetaStat, Inc. (OTCQB : MTST), a life science company focused on understanding and treating systemic metastasis, announced today that the United States Patent and Trademark Office (USPTO) issued on February 4, 2014, U.S. Patent No. 8,642,277 entitled: "TUMOR MICROENVIRONMENT OF METASTASIS (TMEM) AND USES THEREOF IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF TUMORS." The named inventors of this new patent are John Condeelis, Thomas E. Rohan, Frank B. Gertler, and Joan G Jones.
MetaStat, Inc. to Present at the 26th Annual ROTH Conference
Marketwire - Wed Feb 26, 6:15AM CST
MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today that it has been invited to present at the upcoming 26th Annual ROTH Conference. The conference will be held on March 9-12, 2014 at The Ritz-Carlton Laguna Niguel in Dana Point, California. MetaStat will be presenting on Wednesday, March 12, 2014 at 12:30 pm (PT).
Rightscorp Innovative Business Model Persuades File Sharing Users to Pay Intellectual Property Holders: Updates on Recent Coverage
PR Newswire - Tue Feb 25, 6:00AM CST
A California company, Rightscorp, Inc. (OTCQB: RIHT) is receiving the blessing of major music and movie studios by going after illegal distributors on file-sharing sites in a different way than previous enforcement methods. Shareholders seem encouraged as well, especially since this type of low-level piracy is likely to continue.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Metastat Analyst Report Provides Investor Opportunity
PR Newswire - Mon Feb 17, 6:00AM CST
With the tremendous run in the biotech sector over the last 12 months many have overlooked this micro-cap gem that has terrific upside potential. Metastat, Inc. (OTCQB: MTST) is a life sciences company that provides proprietary platform technologies for the treatment of systemic metastasis. This micro-cap stock is topping the list for many analyst in the coming year.
MetaStat, Inc. Launches Scientific Advisory Board for Therapeutics
ACCESSWIRE - Mon Feb 10, 7:00AM CST
MONTCLAIR, NJ / ACCESSWIRE / February 10, 2014 / MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced the appointments of scientific and clinical leaders from the fields of RNA biology, alternative splicing, and therapeutic resistance in cancer to its newly formed scientific advisory board for therapeutics. The members include David M. Epstein, Ph.D, Eric Winer, M.D., Adrian Krainer, Ph.D., Mariano-Garcia Blanco, M.D., Ph.D., Michael Hemann, M.D., Ph.D. and Frank Gertler, Ph.D.
MetaStat, Inc. to Present at the 2014 BIO CEO & Investor Conference in New York City on February 11, 2014
ACCESSWIRE - Wed Feb 05, 8:03AM CST
MONTCLAIR, NJ / February 5, 2014 / ACCESSWIRE / MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced that the company's Chief Executive Officer, Oscar Bronsther, M.D., will present at the BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 1:30 p.m. EST. The conference will be held at the Waldorf Astoria in New York. Dr. Bronsther will discuss MetaStat's novel diagnostic and therapeutic approaches to systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body.
Fundamentals of Endotoxin Testing for Medical Device Manufacturers are Detailed in New Technical Brief
Business Wire - Tue Jan 14, 9:12AM CST
The fundamentals of endotoxin testing for medical device manufacturers -- from definition to assay acceptance criteria --are detailed in new technical brief available from Microtest Laboratories.
MetaStat, Inc. to Present at Biotech Showcase(TM) 2014 in San Francisco
Marketwire - Wed Jan 08, 11:12AM CST
MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced that the company's Chief Executive Officer, Oscar Bronsther, M.D., will present at the Biotech Showcase(TM) 2014 on Wednesday, January 15th at 9:30am PST. Dr. Bronsther will discuss MetaStat's novel diagnostic and therapeutic approaches to systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. To arrange a one-on-one meeting with management, please contact Andrew Haag at mtst@irthcommunications.com or 1-866-976-IRTH.
Fidelity & Guaranty Life Holdings, Inc. Announces Year End 2013 Conference Call for Bondholders
PR Newswire - Tue Jan 07, 8:52AM CST
Fidelity & Guaranty Life Holdings, Inc. ("FGLH") today announced the date and time of its quarterly bondholder conference call for the Fiscal year ended September 30, 2013. The call is open to all holders of Fidelity & Guaranty Life Holdings, Inc. 6.375% senior unsecured notes due 2021.
MetaStat, Inc. Announces Issuance of U.S. Patent for Its MenaCalc(TM) Platform
Marketwire - Mon Dec 23, 7:30AM CST
MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent Number US 8,603,738 entitled: "METASTASIS SPECIFIC SPLICE VARIANTS OF MENA AND USES THEROF IN DIAGNOSIS, PROGNOSIS, AND TREATMENT OF TUMORS", Inventors: John Condeelis, Sumanta Goswami, Frank Gertler, and Paola Nistico.
MetaStat Announces Poster Presentation at the 2013 San Antonio Breast Cancer Symposium
Marketwire - Tue Dec 17, 9:13AM CST
MetaStat, Inc. (OTCBB: MTST), a life sciences company focused on understanding and treating systemic metastasis, today announced data on the company's licensed metastatic breast cancer diagnostic has been presented in Poster Session P2-11-03 entitled "A tumor microenvironment of metastasis (TMEM) biomarker in early breast cancer provides prognostic information that is complementary to IHC4: A prospective validation study" at the CTRC-AACR 2013 San Antonio Breast Cancer Symposium on December 10-14, 2013, in San Antonio, Texas.
MetaStat Announces Exclusive Worldwide License Agreements for the Alternative Splicing Program in the Epithelial to Mesenchymal Transition (EMT) in Epithelial Cancers
Marketwire - Thu Dec 12, 8:30AM CST
MetaStat, Inc. (OTCQB: MTST), a life sciences company focused on understanding and treating systemic metastasis, today announced that the company has entered into two separate exclusive worldwide patent and technology license agreements (the "Agreements") with The Massachusetts Institute of Technology ("MIT") and its David H. Koch Institute for Integrative Cancer Research at MIT and its Department of Biology, Albert Einstein College of Medicine of Yeshiva University, and Montefiore Medical Center. The Agreements cover the use of alternatively spliced mRNA and protein isoform markers for the diagnosis, prognosis and treatment of metastasis in epithelial solid tumor cancers. The company believes this technology bolsters its intellectual property position surrounding the use of the Mena protein isoforms in the diagnosis, prognosis and treatment of metastasis in epithelial cancers. Further, this technology provides MetaStat with a number of additional targets for its companion diagnostic and therapeutic programs.
Microtest Laboratories Offers OECD Fish Embryo Toxicity Testing
PR Newswire - Tue Dec 03, 11:17AM CST
Microtest Laboratories, a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries, is adding OECD Fish Embryo Toxicity Testing to its portfolio of services.
MetaStat, Inc. Announces Notice of Allowance for a U.S. Patent Supporting Its MenaCalc(TM) Platform
Marketwire - Mon Nov 11, 7:41AM CST
MetaStat, Inc. (OTCBB: MTST), a life sciences company focused on understanding and treating systemic metastasis, today announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent entitled: "METASTASIS SPECIFIC SPLICE VARIANTS OF MENA AND USES THEROF IN DIAGNOSIS, PROGNOSIS, AND TREATMENT OF TUMORS." MetaStat holds a license to this patent (US Patent Application. No. 12/462,324), which claims center on the Company's MenaCalc(TM) diagnostic platform. The Notice of Allowance is the USPTO's official communication that the patent application has successfully completed examination and that a patent will be issued. When issued, the patent will have a term that expires no earlier than in 2028.
MetaStat, Inc. Announces Notice of Allowance for a U.S. Patent Supporting Its MetaSite Breast(TM) Test
Marketwire - Wed Nov 06, 7:00AM CST
MetaStat, Inc. (OTCBB: MTST), a life sciences company focused on understanding and treating systemic metastasis, today announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent entitled: "TUMOR MICROENVIRONMENT OF METASTASIS (TMEM) AND USES THEREOF IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF TUMORS." MetaStat holds a license to this patent (US Patent Application. No. 12/804,779), which claims center on the Company's MetaSite Breast(TM) diagnostic assay. The Notice of Allowance is the USPTO's official communication that the patent application has successfully completed examination and that a patent will be issued. When issued, the patent will have a term that expires no earlier than in 2030.
Use of Stability Studies in Drug, Combination Products & Medical Device Development are Reviewed in New Whitepaper
Business Wire - Tue Oct 22, 8:13AM CDT
The use of stability testing in new product development -- of drug substances, drug products, combination products and some medical devices -- is reviewed in a new whitepaper from Microtest Laboratories, a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries.
MetaStat Announces Commencement of Its Comprehensive Drug Development Program with Significant New Hires and Research Facility Opening
ACCESSWIRE - Tue Sep 10, 6:05AM CDT
Montclair, NJ, (Accesswire - September 10, 2013) - MetaStat Inc. (OTCBB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced that it has commenced its comprehensive drug development program with the hiring of Elizabeth Buck, Ph.D. and Matthew O'Connor, both formerly of OSI Pharmaceuticals, Inc. (acquired by Astellas Pharma, Inc.), along with the opening of its new drug discovery research facility located in Stony Brook, NY. Both Dr. Buck and Mr. O'Connor will work closely and in collaboration with Dr. David Epstein, MetaStat's Head of Drug Development and former Chief Scientific Officer of OSI Pharmaceuticals.
